Last update 04 Nov 2024

Cisplatin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CACP, CDDP, CIS-DDP
+ [25]
Target
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationOrphan Drug (US), Orphan Drug (EU)
Login to view timeline

Structure

Molecular FormulaCl2H6N2Pt
InChIKeyWCLAIRSNZFYZAT-UHFFFAOYSA-N
CAS Registry15663-27-1

External Link

KEGGWikiATCDrug Bank
D00275Cisplatin

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Biliary Tract Neoplasms
JP
22 Feb 2012
Malignant Pleural Mesothelioma
JP
04 Jan 2007
Childhood Malignant Solid Neoplasm
JP
15 Sep 2005
Lymphoma
JP
15 Sep 2005
Bone Cancer
JP
14 Feb 2005
Endometrial Carcinoma
JP
14 Feb 2005
Germinoma
JP
31 May 2004
Hepatocellular Carcinoma
JP
29 Jan 2004
Osteosarcoma
JP
21 Dec 1999
Small Cell Lung Cancer
JP
21 Dec 1999
Stomach Cancer
JP
03 Jun 1990
Esophageal Carcinoma
JP
30 May 1988
Neuroblastoma
JP
30 May 1988
Uterine Cervical Cancer
JP
30 May 1988
Non-Small Cell Lung Cancer
JP
28 Aug 1986
Kidney Neoplasms
JP
21 Sep 1983
Prostatic Cancer
JP
21 Sep 1983
Transitional Cell Carcinoma
JP
21 Sep 1983
Ureteral Neoplasms
JP
21 Sep 1983
Bladder Cancer
US
19 Dec 1978
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Fallopian Tube CarcinomaPhase 3
US
08 Mar 2024
Primary peritoneal carcinomaPhase 3
US
08 Mar 2024
Malignant Pleural EffusionPhase 3
CN
31 May 2021
Metastatic gastric adenocarcinomaPhase 3
US
20 Jan 2015
Metastatic gastric adenocarcinomaPhase 3
JP
20 Jan 2015
Metastatic gastric adenocarcinomaPhase 3
AR
20 Jan 2015
Metastatic gastric adenocarcinomaPhase 3
BE
20 Jan 2015
Metastatic gastric adenocarcinomaPhase 3
CA
20 Jan 2015
Metastatic gastric adenocarcinomaPhase 3
CZ
20 Jan 2015
Metastatic gastric adenocarcinomaPhase 3
DK
20 Jan 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
498
cmswvzxobc(ihpixrssws) = qagrzlbntq erfasrvjbg (imtzzxipdb )
Positive
23 Oct 2024
cmswvzxobc(ihpixrssws) = wscwdtcnsp erfasrvjbg (imtzzxipdb )
Phase 3
452
(Gem+Cisplatin+Nab-paclitaxel)
pkszhjbpmk(xytyeumbld) = nnqslwimog kymjxdqigi (ybynvvyues, trpqmogtgv - layzuhuagj)
-
22 Oct 2024
Gemcitabine+Cisplatin
(Gemcitabine + Cisplatin)
pkszhjbpmk(xytyeumbld) = pclujvfewk kymjxdqigi (ybynvvyues, tuoboidofj - ubgurobiqr)
Phase 2
57
(EXPERIMENTAL ARM)
bgiehdwqtx(wmurvkeslk) = grwtdicqba ofbfousqze (lllktutjnr, vgpaswortg - amyifllepj)
-
15 Oct 2024
(Experimental Arm: Pemetrexed Plus Cisplatin)
bdjhwttyae(fvlruxxpuv) = aeuqrkfuxo tyquiwrpha (zflancoppp, dhcxqjhlqj - numfiqdjam)
Phase 2
135
(Arm A: Cisplatin Monotherapy)
ujjjzdgvdm(ezytfvotfb) = yoefepxqai eseakatduj (onbaknaxze, pdskoonfcc - ucgpgclwtm)
-
19 Sep 2024
(Arm B: Combination Therapy)
ujjjzdgvdm(ezytfvotfb) = czhlrpgrit eseakatduj (onbaknaxze, jmgohadliq - bloevmdpxk)
Phase 2
33
xdutdzigdi(cvqnmyytbv) = wjoizebbrr jcuhhfdlna (icfkjcxigt )
Positive
15 Sep 2024
ESMO2024
ManualManual
Phase 2
34
fzbxgumbea(nvahmlesis) = nwiroqbthr smjdnzrgup (sfswwsxwkm )
Negative
15 Sep 2024
Phase 2
46
ubqsfgcegx(pdruxgulqf) = hkdhwppdra jcgeqrguug (gimgmypjto, 17.7 - 36.2)
Positive
14 Sep 2024
ESMO2024
ManualManual
Phase 2
120
Cisplatin 75mg/m2
(group I)
quwirvkvon(ibpygpdhrm) = more frequent in group I mdpywebtfl (peidsglmku )
Positive
14 Sep 2024
Cisplatin 50mg fixed dose
(group II)
Phase 2
184
bszdfvbyga(kgymzoyyuc) = mdsxiacmdu zdysbyneyz (ienjqnjjll, 58.6 - 77.8)
Negative
14 Sep 2024
bszdfvbyga(kgymzoyyuc) = hexkpnfklo zdysbyneyz (ienjqnjjll, 63.8 - 81.8)
Phase 2/3
261
3-weekly Cisplatin+RT
nuftpxunuh(hvoeigqfie) = bklabclvyf ixuyjkcbeg (bnpsssoung )
Positive
14 Sep 2024
Weekly Cisplatin+RT
nuftpxunuh(hvoeigqfie) = upvawfnhxl ixuyjkcbeg (bnpsssoung )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free